Online drug discovery chemicals marketplaces Chemspace and LabNetwork, a WuXi AppTec company, have entered into a collaboration agreement under which LabNetwork’s products will be available on www.chem-space.com, with distribution and technical support provided by Chemspace for European customers, thus expanding the market reach of both companies to pharma and biotech companies.
The Chemspace database encompasses more than 100 million chemical building blocks, fragments and screening compounds, its online catalogue including in-stock and make-on-demand molecules, and offering an easy, fast way to search using a broad range of filter options, such as substructure, similarity, and by using various text identifiers.
Use of the Chemspace database is free-of-charge and global chemistry suppliers, ranging from small to large organisations, are able to upload their catalogues to the site to provide an efficient solution for buyers when sourcing chemicals.
Dr Yurii Moroz, CEO at Chemspace, commented: “The collaboration with LabNetwork will provide drug discovery scientists, medicinal chemists, and academic researchers access to a vast diversity of high-quality products. We see a lot of synergy in our companies combining forces both from a business perspective and also to improve availability of compounds to the research community ultimately to shorten the drug discovery process in the hope of finding better cures for patients, quicker.”
Latest from Tom Mulligan
- EVENT PREVIEW: CPhI North America opens next week!
- NEW BUSINESS: SK biotek and AMPAC Fine Chemicals have ambitious CDMO plans
- NEW TECHNOLOGY: Polyplus-transfection develops GMP-grade therapeutic virus reagent
- Mogrify raises $3.7 million seed funding to support direct cellular conversion for cell therapy
- Owlstone Medical partners with Shanghai Renji Hospital to pioneer Breath Biopsy lung cancer trial
- TECHNOLOGY UPDATE: Catalent invests over $27 million to commercialise next-generation ODT Zydis Ultra
- SGS reports successful Phase 2 results for novel influenza vaccine, validating its H3N2 A/Belgium challenge agent
- NEW TECHNOLOGY: Horizon Discovery and Rutgers University develop new gene editing approach: ‘base editing’
- EVENT REVIEW: Busy sessions at BIO-Europe Spring!
- COMPANY UPDATE: Metrion Biosciences and the potential for ion channel drug discovery